D&P Bioinnovations

What D&P Bioinnovations does

D&P Bioinnovations, Inc. is a privately held, pre-commercial regenerative medicine company founded in 2015 and headquartered in San Diego, California. The company develops an implantable, bioresorbable medical device designed to functionally regenerate a damaged esophagus within the body, avoiding the invasive gastric pull-up surgical reconstruction that is current standard of care. The device combines proprietary stem cell-secreted immunomodulatory factors with dissolvable anti-inflammatory biomaterials, and has been tested in six different diseased animal models demonstrating platform versatility beyond the lead esophageal indication.

The company's technology is positioned as a platform applicable to regenerating damaged blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine. D&P is led by Founder, Inventor, and CEO Dr. Derek C. Dashti (a doctoral NSF Fellow with 19+ years of stem cell tissue engineering research), alongside Co-founder Abbas Dashti, CTO Dr. Nicholas Pashos, Director of Strategy Dr. Karolina Kosakowska, and Data Strategist/Operations lead Dr. Joshua G. Ibarra. The board of advisors includes key opinion leaders such as Dr. Jed Johnson (Nanofiber Solutions) and Dr. Gail Naughton (Histogen).

The business model targets enterprise healthcare providers and hospitals as customers for the lead esophageal implant, with pricing to be determined via commercial partnerships rather than published rates; the value proposition rests on >$240,000 per-treatment cost savings versus gastric pull-up reconstruction. The company addresses a $20 billion U.S. annual market opportunity for severe GERD, advanced Barrett's Esophagus, esophageal cancer, and pediatric congenital defects, within a global regenerative medicine market projected to exceed $200 billion by the late 2020s. Revenue mechanics contemplate both one-time device sales and platform-technology licensing/royalty streams. The company is venture-validated through extensive competition wins (50+ awards across TERMIS, MedTech Innovator, J&J QuickFire, Hello Tomorrow, Rice Business Plan Competition Top 15, European Commission Horizon 2020 Seal of Excellence, MassChallenge, NSF I-CORPS, and others) and partnerships with SanBio, Draper via ARMI, Nanofiber Solutions, Medivet Biologics, Bioaesthetics, and Histogen.

Name

D&P Bioinnovations

Legal name

D&P Bioinnovations, Inc.

Website

https://dpbioinnovations.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

D&P Bioinnovations is a pre-commercial regenerative medicine company developing a bioresorbable stem cell and biomaterial implant to regenerate damaged esophagi, targeting hospitals serving esophageal cancer, severe GERD, and pediatric congenital defect patients.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine devices
• Tissue engineering implants
• Bioresorbable medical devices
• Stem cell technology
• Esophageal regeneration

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Regenerative Implant Device Sales: Revenue expected from sale of regenerative bioengineered implants for esophageal cancer treatment and related applications. Targets a $20 billion U.S. annual market for esophageal conditions including severe GERD, advanced Barrett's Esophagus, esophageal cancer, and pediatric congenital defects.
2. Platform Technology Licensing: Potential licensing revenue from platform technology applicable to regenerating blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine across multiple therapeutic areas.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

D&P Bioinnovations is developing an implantable, bioresorbable medical device that functionally regenerates a damaged esophagus within the body using proprietary stem cell-secreted immunomodulatory factors combined with dissolvable anti-inflammatory biomaterials. The device targets patients requiring esophagectomy (esophageal cancer, severe GERD, advanced Barrett's Esophagus, pediatric congenital defects) as an alternative to invasive gastric pull-up surgical reconstruction. The underlying technology is positioned as a platform with potential application to regenerating blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine.

Product overview

D&P Bioinnovations offers a core product—the D&P Regenerative Bioengineered Esophageal Implant—which is an implantable, bioresorbable medical device designed to functionally regenerate a damaged esophagus. This product sits atop the company's D&P Platform Technology, which serves as a broader regenerative medicine platform capable of addressing multiple tissue types including blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine. The platform technology underlies the esophageal implant as the first therapeutic application, with potential for expansion into other organ regeneration indications.

Differentiator

Problem solved

Functional benefit

Products and services

• D&P Regenerative Bioengineered Esophageal Implant An implantable, bioresorbable medical device that functionally regenerates a damaged esophagus within the body using proprietary stem cell-secreted immunomodulatory factors and dissolvable anti-inflammatory biomaterials. Targets esophageal cancer patients, severe GERD/advanced Barrett's Esophagus patients, and pediatric populations with congenital defects as an alternative to invasive gastric pull-up surgical reconstruction.
• D&P Platform Technology A platform technology for organ and tissue regeneration applicable beyond the esophagus to damaged blood vessels, nerves, muscle, tendons/ligaments, and gastro-intestine, using D&P Bioinnovations' proprietary stem cell-secreted immunomodulatory factors and dissolvable anti-inflammatory biomaterials. Designed to be licensed or extended into additional therapeutic areas.

Quantifiable outcome

• Saves over $240,000 per treatment compared to standard gastric pull up surgery
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, moderate and minor.

• SanBiocoreStrategic or Co-development Partner · 1 November 2021Partnership with SanBio, a regenerative medicine company, announced in November 2021. SanBio is a previous partner logo that became an active partnership for potential collaboration in regenerative medicine technologies.
• Draper (via ARMI)coreStrategic or Co-development PartnerDraper (through ARMI membership) is a strategic partner. Draper is listed as a partner logo on the company website. ARMI (Advanced Regenerative Manufacturing Institute) is a National Institute that D&P Bioinnovations is inducted into as member since December 2018.
• Nanofiber SolutionsmoderateTechnology or IntegrationNanofiber Solutions developed materials for the world's first implantable trachea. Listed as a partner with Dr. Jed Johnson (founder & CTO of Nanofiber Solutions) serving on D&P Bioinnovations Board of Advisors.
• Medivet BiologicsmoderateStrategic or Co-development PartnerListed as a partner on company website. Medivet Biologics is a regenerative medicine/biologics company.
• BioaestheticsminorStrategic or Co-development PartnerListed as a partner on company website. Bioaesthetics is a biotech company in the regenerative medicine space.
• Armi (Advanced Regenerative Manufacturing Institute)coreStrategic or Co-development PartnerPrevious partner listed on company website. D&P Bioinnovations is an inducted member of ARMI since December 2018. ARMI is a National Advanced Regenerative Manufacturing Institute focused on regenerative medicine manufacturing.
• HistogenminorStrategic or Co-development PartnerPrevious partner listed on company website. Dr. Gail Naughton, CEO of Histogen and Chairman of the Board for Histogen, serves on D&P Bioinnovations Board of Advisors. Histogen has over 25 years of tissue engineering research experience.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Humacyte: Clinical-stage regenerative medicine company developing bioengineered human tissues including vascular grafts. Closely comparable to D&P as it combines cells/scaffolds into implantable regenerative products targeting large surgical markets, and shares a similar preclinical-to-commercial translation profile.
• Vericel: Commercial-stage cell therapy company marketing autologous cell-based products (MACI for cartilage repair, Epicel for burns). Directly comparable as a regenerative medicine company using cell-based and tissue-engineering approaches to address surgical indications.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapies for inflammatory and tissue damage indications. Directly comparable as a stem-cell-based regenerative medicine peer pursuing multi-indication platform claims.
• Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived mesenchymal stem cells for regenerative applications across multiple indications. Comparable as a multi-indication, stem-cell-based regenerative medicine platform.

Broad incumbents

• Organogenesis: Established regenerative medicine company marketing wound care and surgical biologics (Apligraf, Dermagraft). Comparable as a commercial-stage regenerative medicine peer serving hospitals and surgical centers with bioengineered tissue products.
• Cook Medical: Large privately-held medical device manufacturer with an established esophageal stent portfolio. Comparable as an incumbent addressing the same esophageal disease space (GERD, strictures, cancer) that D&P targets with a regenerative approach.
• Boston Scientific:

Emerging players

• MiMedx: Commercial-stage regenerative medicine company marketing placental tissue allografts for wound care and surgical applications. Comparable as a regenerative medicine peer using biomaterial-based approaches to drive tissue repair across multiple surgical indications.
• Sigilon Therapeutics: Clinical-stage cell encapsulation and regenerative medicine company. Comparable as an early-stage platform regenerative medicine peer combining cells/biomaterials to address tissue damage, sharing D&P's preclinical-to-clinical profile.

Others

• Nanofiber Solutions: Biomaterials company that developed materials for the world's first implantable trachea and is an existing D&P partner. Directly comparable as a biomaterial/scaffold technology provider in the regenerative medicine space and an active collaborator on the D&P platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/dp_b1o

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D&P Bioinnovations